VIVORYON THERAPEUTICS N.V. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4855 EUR | +1.15% |
|
-3.29% | -94.04% |
| Sales 2023 * | - | Sales 2024 * | - | Capitalization | 12.51M 13.29M |
|---|---|---|---|---|---|
| Net income 2023 * | -23M -24.44M | Net income 2024 * | -18M -19.13M | EV / Sales 2023 * | - |
| Net cash position 2023 * | 24.1M 25.61M | Net cash position 2024 * | 19.55M 20.77M | EV / Sales 2024 * | - |
| P/E ratio 2023 * |
-0.53
x | P/E ratio 2024 * |
-0.69
x | Employees | 15 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.82% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vivoryon Therapeutics N.V.
More press releases
| 1 day | -3.03% | ||
| 1 week | -7.51% | ||
| Current month | -11.11% | ||
| 1 month | -14.13% | ||
| 3 months | -93.85% | ||
| 6 months | -95.63% | ||
| Current year | -94.10% |
1 week
0.48
0.53
1 month
0.480.57
Current year
0.489.93
1 year
0.4819.56
3 years
0.4823.25
5 years
0.4823.25
10 years
0.4827.73
| Managers | Title | Age | Since |
|---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
| Director/Board Member | 56 | 18-08-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 74 | 06-12-31 | |
| Director/Board Member | 54 | 06-12-31 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-16 | 0.4855 | +1.15% | 20 840 |
| 24-04-15 | 0.48 | -3.03% | 177,586 |
| 24-04-12 | 0.495 | -1.20% | 128,496 |
| 24-04-11 | 0.501 | -0.60% | 95,643 |
| 24-04-10 | 0.504 | +0.40% | 150,543 |
Real-time Euronext Amsterdam, April 15, 2024 at 11:35 am EDT
More quotes
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease.
At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
Calendar
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.495
EUR
Average target price
41.57
EUR
Spread / Average Target
+8,297.31%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -94.10% | 13.73M | |
| -0.13% | 42.63B | |
| +50.98% | 42.32B | |
| +4.53% | 40.26B | |
| -11.36% | 27.27B | |
| +5.72% | 25.24B | |
| -22.90% | 18.78B | |
| -0.63% | 12.39B | |
| +26.95% | 12.24B | |
| +7.04% | 10.95B |
- Stock Market
- Equities
- VVY Stock
